Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass

International Journal of Obesity

Volumn 36, Issue 3, 2012, Pages 379-384

  Fenske, W K ^a,b   Bueter, M ^a,c   Miras, A D ^a   Ghatei, M A ^a   Bloom, S R ^a   Le Roux, C W ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

bariatric surgery; GLP 1; gut hormone response; PYY; Roux en Y gastric bypass surgery

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; OCTREOTIDE; PEPTIDE YY [3-36]; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FOOD INTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; ROUX Y ANASTOMOSIS; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; APPETITE DEPRESSANTS; APPETITE REGULATION; APPETITE STIMULANTS; EATING; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; OBESITY; OCTREOTIDE; PEPTIDE YY; PEPTIDES; POSTOPERATIVE PERIOD; RATS; SATIATION; VENOMS;

RATTUS;

EID: 84858294193     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.126     Document Type: Article

References (41)

1. Sjostrom L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752. (Pubitemid 47295641)
2. Ashrafian H, le Roux CW. Metabolic surgery and gut hormones-Fa review of bariatric entero-humoral modulation. Physiol Behav 2009; 97: 620-631.
3. Tadross JA, le Roux CW. The mechanisms of weight loss after bariatric surgery. Int J Obes (Lond) 2009; 33(Suppl 1): S28-S32.
4. Bueter M, Löwenstein C, Olbers T, Wang M, Cluny NL, Bloom SR et al. Gastric bypass increases energy expenditure in rats. Gastroenterology 2010; 138: 1845-1853.
5. Orlando FA, Goncalves CG, George ZM, Halverson JD, Cunningham PR, Meguid MM. Neurohormonal pathways regulating food intake and changes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1: 486-495.
6. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246: 780-785. (Pubitemid 350035654)
7. le Roux CW, Borg C, Wallis K, Vincent RP, Bueter M, Goodlad R et al. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg 2010; 252: 50-56.
8. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108-114. (Pubitemid 43054062)
9. Pittner RA, Moore CX, Bhavsar SP, Gedulin BR, Smith PA, Jodka CM et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 2004; 28: 963-971. (Pubitemid 38998700)
10. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.
11. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005; 146: 3748-3756. (Pubitemid 41175742)
12. Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM. Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring) 2011; 19: 121-127.
13. Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 2010; 92: 810-817.
14. Field BC,Wren AM, Peters V, Baynes KC, Martin NM, Patterson M et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59: 1635-1639.
15. Bueter M, Löwenstein C, Ashrafian H, Hillebrand J, Bloom SR, Olbers T et al. Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass. Obes Surg 2010; 20: 616-622.
16. Batterham RL, Cohen MA, Ellis SM, le Roux CW,Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948. (Pubitemid 37064767)
17. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28: 166-170. (Pubitemid 17027386)
18. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304. (Pubitemid 17156636)
19. Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz P. Proceedings: radioimmunoassay of a new gut hormone-human pancreatic polypeptide. Gut 1976; 17: 393-394.
20. Chelikani PK, Haver AC, Reidelberger RD. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R39-R46. (Pubitemid 47092160)
21. Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM. Effects of Exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring) 2011; 19: 121-127.
22. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2006; 291: R367-R375. (Pubitemid 44035643)
23. Koegler FH, Enriori PJ, Billes SK, Takahashi DL, Martin MS, Clark RL et al. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 2005; 54: 3198-3204. (Pubitemid 43334375)
24. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006; 30: 1332-1340. (Pubitemid 44306514)
25. Kwak HH, Shim WS, Hwang S, Son MK, Kim YJ, Kim TH et al. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharm Res 2009; 26: 2504-2512.
26. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.
27. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259-267.
28. Magro DO, Geloneze B, Delfini R, Pareja BC, Callejas F, Pareja JC. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg 2008; 18: 648-651.
29. Christou NV, Look D, Maclean LD. Weight gain after short-and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2006; 244: 734-740. (Pubitemid 44629947)
30. Gumbs AA, Pomp A, Gagner M. Revisional bariatric surgery for inadequate weight loss. Obes Surg 2007; 17: 1137-1145. (Pubitemid 351321333)
31. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007; 142: 621-632; discussion 632-635.
32. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
33. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181. (Pubitemid 40674548)
34. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353: 249-254. (Pubitemid 41058324)
35. Alvarez GC, Faria EN, Beck M, Girardon DT, Machado AC. Laparoscopic spleen-preserving distal pancreatectomy as treatment for nesidioblastosis after gastric bypass surgery. Obes Surg 2007; 17: 550-552. (Pubitemid 46850198)
36. Clancy TE, Moore Jr FD, Zinner MJ. Post-gastric bypass hyperinsulinism with nesidioblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg 2006; 10: 1116-1119. (Pubitemid 44332983)
37. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 2002; 87: 1797-1804. (Pubitemid 34615271)
38. Rudholm T, Wallin B, Theodorsson E, Näslund E, Hellström PM. Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. Regul Pept 2009; 152: 8-12.
39. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 5120-5127. (Pubitemid 41653025)
40. Proulx K, Cota D, Castañeda TR, Tschöp MH, D'Alessio DA, Tso P et al. Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. Am J Physiol Regul Integr Comp Physiol 2005; 289: R729-R737. (Pubitemid 41208437)
41. Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC et al. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 2000; 20: 1616-1621. (Pubitemid 30220440)